EAM Investors LLC Invests $754,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

EAM Investors LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 222,377 shares of the company’s stock, valued at approximately $754,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth $42,000. Cibc World Markets Corp purchased a new stake in Xeris Biopharma during the fourth quarter worth $44,000. Raymond James Financial Inc. acquired a new stake in Xeris Biopharma in the 4th quarter valued at about $45,000. Virtu Financial LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $58,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Xeris Biopharma by 1,496.3% in the fourth quarter. Russell Investments Group Ltd. now owns 17,974 shares of the company’s stock worth $61,000 after acquiring an additional 16,848 shares during the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.56% of the stock is owned by insiders.

Xeris Biopharma Stock Up 0.7 %

Shares of XERS opened at $4.11 on Friday. The firm has a market cap of $632.69 million, a PE ratio of -9.13 and a beta of 1.37. The company’s fifty day moving average is $4.43 and its two-hundred day moving average is $3.68. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $1.69 and a fifty-two week high of $6.07.

Analysts Set New Price Targets

Several research analysts recently weighed in on XERS shares. Leerink Partners boosted their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Craig Hallum lifted their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday, March 7th. Jefferies Financial Group reissued a “buy” rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $6.10.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.